Stockreport

Repare Therapeutics eyes Phase III cancer study after Mythic trial success [Yahoo! Finance]

Repare Therapeutics Inc. - Common Shares  (RPTX) 
PDF from its Phase I gynecologic expansion trial evaluating Lunre+Camo, a combination of lunresertib and camonsertib, in patients with endometrial cancer and ovarian cancer. [Read more]